Immunitybio Stock Performance
| IBRX Stock | USD 2.96 0.05 1.66% |
On a scale of 0 to 100, Immunitybio holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.86, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunitybio will likely underperform. Please check Immunitybio's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immunitybio's current trending patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunitybio are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Immunitybio showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.14) | Five Day Return 8.27 | Year To Date Return 17.12 | Ten Year Return (91.31) | All Time Return (91.31) |
1 | Why ImmunityBio, Inc. Is the Top Small Cap Stock to Buy with the Highest Upside Potential | 01/13/2025 |
2 | Disposition of 110020 shares by Simon Barry J. of Immunitybio at 1.9984 subject to Rule 16b-3 | 01/22/2025 |
3 | Disposition of 83333 shares by Richard Adcock of Immunitybio subject to Rule 16b-3 | 01/24/2025 |
4 | ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch | 01/29/2025 |
5 | Acquisition by Richard Adcock of 822368 shares of Immunitybio subject to Rule 16b-3 | 02/10/2025 |
6 | Acquisition by Regan Lauer of 56250 shares of Immunitybio at 3. subject to Rule 16b-3 | 02/12/2025 |
7 | Acquisition by Richard Adcock of 1524 shares of Immunitybio subject to Rule 16b-3 | 02/25/2025 |
8 | ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care ChemotherapyRadiotherapy... | 02/28/2025 |
9 | Tesla Rebounds While Tariffs Weigh On Manufacturing Whats Driving Markets Monday | 03/03/2025 |
10 | Why ImmunityBio Inc. Crashed on Monday | 03/04/2025 |
11 | How ImmunityBio, Inc. Is Navigating Market Trends and Institutional Shifts | 03/06/2025 |
12 | ImmunityBio, Inc. Among the Stocks Under 10 With High Upside Potential | 03/12/2025 |
13 | ImmunityBio Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching | 03/13/2025 |
14 | Acquisition by Regan Lauer of 65744 shares of Immunitybio subject to Rule 16b-3 | 03/14/2025 |
15 | Investor Alert Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio Johnson Fistel, PLLP Investigates Claims on Behalf of Investors | 03/24/2025 |
16 | ImmunityBio to Host Investor Day | 03/26/2025 |
17 | ImmunityBio Stock Price Up 10.6 percent Whats Next | 03/27/2025 |
| Begin Period Cash Flow | 265.8 M |
Immunitybio |
Immunitybio Relative Risk vs. Return Landscape
If you would invest 257.00 in Immunitybio on January 1, 2025 and sell it today you would earn a total of 39.00 from holding Immunitybio or generate 15.18% return on investment over 90 days. Immunitybio is currently generating 0.4545% in daily expected returns and assumes 6.9525% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Immunitybio, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunitybio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunitybio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunitybio, and traders can use it to determine the average amount a Immunitybio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0654
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IBRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.95 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.45 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Immunitybio is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunitybio by adding it to a well-diversified portfolio.
Immunitybio Fundamentals Growth
Immunitybio Stock prices reflect investors' perceptions of the future prospects and financial health of Immunitybio, and Immunitybio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunitybio Stock performance.
| Return On Asset | -0.48 | ||||
| Operating Margin | (9.19) % | ||||
| Current Valuation | 2.92 B | ||||
| Shares Outstanding | 853.44 M | ||||
| Price To Sales | 181.74 X | ||||
| Revenue | 14.74 M | ||||
| Gross Profit | 14.74 M | ||||
| EBITDA | (264.43 M) | ||||
| Net Income | (413.64 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 42.29 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.57) X | ||||
| Cash Flow From Operations | (391.24 M) | ||||
| Earnings Per Share | (0.62) X | ||||
| Market Capitalization | 2.68 B | ||||
| Total Asset | 382.93 M | ||||
| Retained Earnings | (3.38 B) | ||||
| Working Capital | 129.64 M | ||||
About Immunitybio Performance
Evaluating Immunitybio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunitybio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunitybio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 357.86 | 318.10 | |
| Return On Tangible Assets | (1.13) | (1.18) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (1.08) | (1.13) | |
| Return On Equity | 0.85 | 0.89 |
Things to note about Immunitybio performance evaluation
Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunitybio had very high historical volatility over the last 90 days | |
| Immunitybio currently holds 42.29 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 14.74 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 63.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: ImmunityBio Stock Price Up 10.6 percent Whats Next |
- Analyzing Immunitybio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunitybio's stock is overvalued or undervalued compared to its peers.
- Examining Immunitybio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunitybio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunitybio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunitybio's stock. These opinions can provide insight into Immunitybio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.